Avita, with the recent acquisitions, now provides on-site and central fill pharmacy services through more than 60 pharmacies, with over 250 covered entity relationships that serve more than 120,000 patients
Emory Healthcare’s Specialty Pharmacy Service was established to meet the needs of patients and providers, in the setting of an evolving healthcare landscape
Centurion provides correctional healthcare and staffing services to government agencies in 17 states
VA Extending Hepatitis C Therapy as its drug spend for the disease increases rapidly. The department last year allocated $696 million for new hepatitis C drugs, accounting for 17 percent of the VA’s total pharmacy budget. In fiscal 2016, which began Oct. 1, 2015, the VA expects to spend about $1 billion on hepatitis C […]
Planning a Specialty Drug Strategy Through 2020 – Traditional approaches are not suited to managing the cost of specialty drug therapies By Gregory Judd, CEBS, and Randy Vogenberg, PhD 5/4/2015 (originally published by Society for Human Resource Management (SHRM)) The specialty drug tsunami is picking up strength and is about to come crashing down on […]
Amid the constant change churning the health care marketplace, employers have the opportunity to use value-based tactics to get more for their health benefits, including pharmaceutical spending that is currently the biggest driver of rising health care costs. That message was echoed by all four speakers at the Alliance Learning Circle on “Doses and Dollars: […]
“[Hepatitis C] is a very competitive market, as a number of companies are looking to compete with Gilead’s products due to the large population of patients and the high earnings potential for drug sales,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries. Read more here: http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/top-five-industry-challenges-2015?page=0,7
Gilead Sciences’ ($GILD) hep C drug Sovaldi burst onto the market, impressing doctors and patients with its benefits and outraging payers and politicians with its price. It reached blockbuster status twice over in the course of a single quarter. But instead of an aberration, a new report suggests it is a reflection of a trend that has […]